Scotiabank raises CrowdStrike stock price target on strong growth

CrowdStrike shares are lifted by a strong post-earnings analyst wave: Scotiabank raised its price target to $250 from $227 (Sector Outperform) as the firm pointed to Q2 net new ARR accelerating to 51% YoY growth and a 34% new ARR target for FY2027. Multiple analysts increased targets after results, citing ARR strength (e.g., TD Cowen/Baird/Mizuho pointing to ~25% total ARR growth and rising ARR figures) and management’s view that there was no unusual deal timing. Overall, the updates reinforce a bullish outlook for CrowdStrike as enterprises ramp spending to modernize security and defend against AI threats.

Analysis

The important signal is not that security demand is healthy; it is that AI is turning cybersecurity into a forced upgrade cycle, which lets platform vendors convert fear into higher module attach and larger contract sizes. That favors CRWD over narrower point solutions and over slower-moving legacy vendors, because budget is more likely to consolidate around a few control points than expand evenly across the stack. If this persists, the second-order loser is not just incumbents like PANW/FTNT/ZS, but also smaller niche tools that sit adjacent to endpoint, identity, and data protection.

Near term, the stock can keep working because analyst revisions create a reflexive loop, but the multiple already implies several quarters of execution without a stumble. The key market mechanism to watch is whether new ARR acceleration is truly broad-based or just a timing shift from customers pulling forward security spend ahead of AI deployment. If the next two quarters show deceleration in net new ARR or weaker large-deal conversion, the premium valuation is vulnerable to a fast reset even if revenue stays strong.

Contrarian view: the market may be overestimating how much incremental AI-security spend is additive versus reallocated from existing security budgets. In other words, this may be a share-gain story more than a TAM-expansion story. NVDA remains the cleaner AI beneficiary; this note is only a second-order read-through for compute, while TGT has no meaningful exposure and should be ignored as noise.

Key Decisions for Investors

• Buy CRWD on 3-6 month pullbacks, not strength; target a move toward $230-$250 if new ARR stays >40% and enterprise demand remains broad, but cut risk if guidance implies post-2027 deceleration.
• Use a 4-6 month CRWD call spread (e.g., 190/250) to express the compounder thesis while limiting downside from an expensive multiple.
• Pair trade: long CRWD / short ZS over the next 1-3 months to express platform consolidation versus adjacent security spend; thesis breaks if checks show budget expanding into broader cloud/data-security rather than endpoint-led consolidation.
• Do not add to NVDA on this headline alone; it is a cleaner AI capex beneficiary than a downstream security budget story. Only buy on broader AI-capex weakness, not on CRWD-style analyst revisions.